Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on BASILEA PHARMACEUTICA-REG. We currently have 4 research reports from 1 professional analysts.
|20Feb17 06:15||GNW||Basilea reports solid 2016 results and expects to double product sales in 2017|
|29Dec16 06:15||GNW||Basilea names new member of its Extended Management Committee|
|02Dec16 06:15||GNW||Basilea expands oncology drug candidate BAL101553 clinical phase 1/2a oral study to include glioblastoma patients|
|15Nov16 06:15||GNW||Basilea's antifungal Cresemba® (isavuconazole) launched in France|
|20Sep16 06:15||GNW||Basilea announces distribution agreement with Unimedic for CRESEMBA® (isavuconazole) and Zevtera® (ceftobiprole) in the Nordic countries|
|15Sep16 06:15||GNW||Basilea announces partnership for antifungal isavuconazole in Japan with Asahi Kasei Pharma|
|13Sep16 06:15||GNW||Basilea announces supply, distribution and license agreement with Grupo Biotoscana for CRESEMBA® (isavuconazole) and Zevtera® (ceftobiprole) in Latin America|
Frequency of research reports
Research reports on
Licensing double act
16 Sep 16
Basilea continues to make good partnering progress with key assets Cresemba for mould infections and Zevtera for bacterial infections. Both drugs will be developed and marketed across Latin America by Grupo Biotoscana (GBT), while Cresemba will be developed and marketed by Asahi Kasei Pharma in Japan. Basilea will receive a total upfront of CHF18m (to be treated as deferred revenue over a number of years), plus additional payments on reaching regulatory and commercialisation milestones (up to CHF60m from Asahi plus royalties, undisclosed amounts from GBT). We value Basilea at CHF1,091m.
Moving on up
30 Aug 16
Basilea has made a solid start to the first half of 2016, with anti-microbial agents Cresemba and Zevtera continuing their respective European roll-outs. Ongoing dialogue with the FDA on the SPA protocol for Zevtera’s Phase III US clinical trial programme means US trials should initiate in H117. Together, these underpin the current valuation with upside potential from further partnering deals for Cresemba, Zevtera and the early-stage oncology pipeline, which in itself is making progress, albeit at an early stage. We value Basilea at CHF1,091m or CHF101/share.
Zevtera US development full steam ahead
22 Apr 16
Basilea has announced that BARDA, a division of the US Department of Health & Human Services Office, has awarded a contract of up to $100m for the Phase III development of antibacterial agent ceftobiprole (Zevtera) for the US market. Critically, this means that the Phase III trials in skin and bacteraemia (blood) infections could start as soon as late 2016/early 2017 once the company has agreed the Phase III study Special Protocol Assessments (SPAs) with the FDA. The BARDA contract now removes the uncertainty in timing for the Phase III clinical trial programme that would support Zevtera’s US regulatory filing. We value Basilea at CHF1,114m or CHF103.2/share.
Riding the crest of the novel antimicrobial wave
23 Mar 16
Basilea is one of the few standalone European companies focused on developing novel antimicrobial drugs. It has two approved hospital-based products: Cresemba for severe mold infections and Zevtera for bacterial infections. Together these underpin the current valuation with upside potential from a US partnering deal for Zevtera and the early-stage oncology pipeline. A US Zevtera deal and potential sales progression for the antimicrobial portfolio are key near-term share price drivers. We value Basilea at CHF1,114.0m or CHF103.2/share.
Panmure Morning Note 15-02-2017
15 Feb 17
With the early January trading update having prompted us to upgrade forecasts, today’s interim results show how the group’s focus on areas such as product development and international sales are translating through to growth in both the top and bottom-line. The consistency of delivery is what impresses us, reflecting the maturity of the management team and the clarity of the longterm vision. We repeat our Buy recommendation.
Panmure Morning Note 15-02-2017
15 Feb 17
We expect Vernalis to report interim results to December on 21st February. We adjust our forecasts slightly ahead of the results, taking into account the $3m milestone payment from Corvus received yesterday, a slightly more cautious outlook for FY Tuzistra sales and the effect of exchange. We expect results to focus on Tuzistra and also the outlook for the 2017-18 season when we expect Vernalis to have 3 cough-cold products on the market. We maintain our BUY recommendation and 65p price target.
Small Cap Breakfast
15 Feb 17
Xafinity –Publication of prospectus. The pensions actuarial, consulting and administration business has conditionally raised £179.6m. At 139p. Due to join main market 16 Feb. Guinness Oil & Gas Exploration—Publication of prospectus. Seeking to raise £50m and invest in 15 exploration companies at launch, with plans to grow the portfolio to 30 positions during its lifetime. Issue closing 23 Feb. Arix Bioscience — Intention to float on the main market from the global healthcare and life science company supporting medical innovation. Raised £52m in Feb 16 with investors including Woodford Investment Management
Panmure Morning Note 20-02-2017
20 Feb 17
Chi-Med has announced the initiation of a Phase II study of savolitinib in locally advanced or metastatic pulmonary sarcomatoid carcinoma (PSC) in China. This is a disease where patients are usually diagnosed by normal pathology (i.e. not via molecular diagnostics methods) but given that 20-30% of PSC patient show c-Met gene amplification this potentially represents a very rich patient pool for savolitinib as a highly selective and potent oral c-Met inhibitor. The continued strength of Chi-Med’s clinical momentum is further demonstrated by today’s news and we consider this represents further upside potential against our existing investment case. We repeat our Buy recommendation.
Capital increase to support accelerated growth
14 Feb 17
Collagen Solutions is a biomaterials company developing and manufacturing medical grade collagen components for use in medical devices, research, and regenerative medicine. A number of investment initiatives have been introduced over the last year to accelerate the rate of growth, including global commercial infrastructure and the development of a pipeline of finished medical devices. The company has announced a capital increase, as well as some strategic investor venture debt, to raise gross funds of up to £12.0m to fund these initiatives, with a target of generating a five-fold sales increase over 5 years and profitability in 2019.
N+1 Singer - Morning Song 21-02-2017
21 Feb 17
Abzena (ABZA LN) Contract bookings strong; US costs higher than expected | City of London Investment Group (CLIG LN) Earnings and interim dividend in line, some modest growth in FuM | dotdigital Group (DOTD LN) Good H1; broadening avenues of growth | Grafenia (GRA LN) Weak print volumes | Vernalis (VER LN) Interims highlight increasing Tuzistra™ scrip volume